Does HbF induction by hydroxycarbamide work through MIR210 in sickle cell anaemia patients?
National Institute of Immunohaematology (ICMR), Mumbai, India.
Madhavi
M
Sawant
Department of Haematology, KEM Hospital, Mumbai, India.
Chandrakala
C
S
National Institute of Immunohaematology (ICMR), Mumbai, India.
Roshan
R
Colah
National Institute of Immunohaematology (ICMR), Mumbai, India.
Kanjaksha
K
Ghosh
National Institute of Immunohaematology (ICMR), Mumbai, India. anitahnadkarni@yahoo.com.
Anita
A
Nadkarni
D000755:Anemia, Sickle Cell / Q000188:drug therapy / Q000235:genetics*; D005319:Fetal Hemoglobin / Q000235:genetics*; D006801:Humans; D006918:Hydroxyurea / Q000494:pharmacology*; D035683:MicroRNAs / Q000502:physiology*; D015533:Transcriptional Activation / Q000187:drug effects
C543800:MIRN210 microRNA, human; D035683:MicroRNAs; D005319:Fetal Hemoglobin; D006918:Hydroxyurea
HBG2; HbF; MIR210; hydroxycarbamide; sickle cell anaemia